Tag Archives: TEM

Tempus AI Projects 83% Revenue Surge for 2025; Total Contract Value Hits Record High of Over $1.1 Billion

Leave a reply

Tempus AI (TEM), a leading technology company dedicated to advancing precision medicine through artificial intelligence, saw its shares jump more than 12% in early trading.

The rally followed the company’s release of its preliminary, unaudited financial summary for the fourth quarter and full year ended December 31, 2025. Tempus reported 2025 revenue of approximately $1.27 billion, representing a year-over-year increase of about 83%. Organic growth, excluding contributions from the Ambry Genetics acquisition, stood at approximately 30%.

Segment Performance and Growth Drivers

According to the preliminary data, the company’s Genomics (Diagnostics) business generated approximately $955 million in revenue for 2025, up 111% year-over-year. This growth was primarily driven by a 26% increase in oncology testing volume and a 29% increase in hereditary testing volume.

The Data and Services (Data & Applications) business reached $316 million in revenue, a 31% increase year-over-year, largely supported by a 38% growth in its Insights business.

Furthermore, Tempus AI announced that its Total Contract Value (TCV) exceeded $1.1 billion as of December 31, 2025, marking a new record for the company.

Fourth Quarter Highlights

For the fourth quarter of 2025, Tempus recorded revenue of approximately $367 million, an 83% increase year-over-year:

  • Genomics (Diagnostics): Revenue was approximately $266 million, up 121%, driven by a 29% rise in oncology testing and a 23% rise in hereditary testing volume.
  • Data and Services: Revenue reached approximately $100 million, a 25% increase. Notably, excluding the impact of the AstraZeneca warrants from Q4 2024, the Insights business grew by 68%.

CEO Commentary and 2026 Outlook

“2025 was an exceptional year for Tempus, with both of our product lines exceeding the expectations we set at the beginning of the year,” said Eric Lefkofsky, Founder and CEO of Tempus. “In our Diagnostics business, volume growth for our genomics (oncology) products has accelerated for three consecutive quarters, reaching its highest unit growth rate in years.”

Lefkofsky added, “Our Data and Services business performed even more strongly, with Q4 revenue hitting a record $100 million. We enter 2026 with extraordinary momentum, as growth in both core businesses accelerates and begins to unlock the financial leverage inherent in our platform. With AI serving as a catalyst across all our products, we are very excited for the year ahead.”